NVIV - InVivo Therapeutics Holdings Corp.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development11,08312,55710,058
Selling General and Administrative13,51011,50612,340
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-24,593-24,063-22,398
Income from Continuing Operations
Total Other Income/Expenses Net-2,078780-10,744
Earnings Before Interest and Taxes-26,671-23,283-33,142
Interest Expense74155172
Income Before Tax-26,745-23,438-33,314
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-26,745-23,438-33,314
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-26,745-23,438-33,314
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-26,745-23,438-33,314